CytomX Therapeutics Inc (CTMX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, CytomX Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of 81.1%.
Historical revenue and profitability trends for CytomX Therapeutics Inc
The chart above illustrates CytomX Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of CytomX Therapeutics Inc's business.
How efficiently CytomX Therapeutics Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue CytomX Therapeutics Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project CytomX Therapeutics Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.1667 based on 6 analysts.
Based on our comprehensive analysis, CytomX Therapeutics Inc (CTMX) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of CytomX Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how CytomX Therapeutics Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: CTMX Valuation, CTMX Dividend, CTMX Financial Health
Compare: CTMX vs AAPL, CTMX vs MSFT, CTMX vs GOOGL